Please assess the completion status of the following clinical trial:

Trial Title: DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 months to 68 months inclusive (recommended 3 to 8 months for Groups A and B; 2 months for Group C) on the day of inclusion~* Informed consent form signed by the parent(s) or other legal representative~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Fever ≥ 37.5°C (axillary temperature) on the day of inclusion~* Any serious disease whether acute or chronic~* Past or current medical history of Guillain-Barre syndrome, acute thrombocytopenic purpura or encephalopathy~* History of diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b infections~* History of a life threatening reaction to a vaccine containing the same substances of the study vaccine~* History of anaphylaxis to any of the study vaccine components~* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis or Haemophilus influenzae type b infections with a trial vaccine or another vaccine~* Congenital or current acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Participation in another clinical trial preceding the trial inclusion~* Planned participation in another clinical trial during the present trial period~* Blood or blood-derived products received in the past or current or planned administration during the trial (including immunoglobulins)~* Any vaccination with live vaccines within the past 27 days preceding the first trial vaccination~* Any vaccination with inactivated vaccines within the past 6 days preceding the first trial vaccination~* Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or HIV infection~* Subject ineligible according to the Investigator's clinical judgment~* Identified as employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family member (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 68 Months
- Healthy Volunteers: t

Study Arms:
- Group A (SP0204) (Type: EXPERIMENTAL): Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously
- Group B (control) (Type: ACTIVE_COMPARATOR): Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously
- Group C (Type: EXPERIMENTAL): Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).